PHSE, leading company in pharmaceutical logistics, strengthens its presence in the italian market through the acquisition of Duimex, active in temperature-controlled transport of clinical trials, biological samples and in the management of “special services”
PHSE, a leading company in pharmaceutical logistics controlled by entrepreneur Eddy De Vita and participated in by NB Aurora – which indirectly holds a 30.8% stake – as well as by the three founding partners Andrea Cerchia, Carlo Cerchia and Gianluca Meneguzzi, announces that it has acquired the 100% of Duimex, an Italian company based in Peschiera Borromeo, active in national and international temperature-controlled transport, with strong specialization in the logistics of “same day” special services, clinical trials and biological samples.
Since 1996 Duimex has served the research, clinical, diagnostic and hospital community extensively. Its distribution capability is made up of 45 direct employees, a refrigerated GDP logistics hub on the outskirts of Milan and 40 temperature-controlled vehicles, through which Duimex provides highly specialized services ranging from the transport of life-saving pharmaceutical products to the the delicate transfer of stem cells to patients. Duimex closed 2020 reaching revenues of around 3.4 million euros, 70% of which with hospitals and diagnostic centers, confirming a constant growth trend in recent years.
The transaction was concluded a few months after the recent acquisitions of the English Tek Freight and the Rapida Time & Temperature in Indiaconfirming a strong acceleration in the expansion of its global network, but also a strong focus on strengthening its portfolio of high value added services in support of pharmaceutical research and clinical studies, where Italy in particular plays an important and growing role with more than 700 million euros per year invested by the pharmaceutical industry.
Duimex’s skills will allow PHSE Group, which has always been a pioneer in biopharmaceutical logistics, to expand its clientele in the public and private hospital sector and to further strengthen its operational, organizational and technological base, as well as providing an increasingly “data-centric” service to its customers: research institutes, laboratories, experimental centers, pharmaceutical companies and blood banks.
Duimex, in line with the regulatory requirements of the pharmaceutical industry, in particular related to the guarantee of traceability and compliance with temperature, has fleet of vehicles, all equipped with a self-contained refrigerating unit bulkhead and with GPS satellite detection systems capable of collecting continuous information on the position and temperature of the vehicle (constantly recorded by probes installed inside the load compartment), made available in real time on a dedicated tracking platform.
Eddy De Vita, Presidente di PHSE, has commented : “With around 300 products under development, pharmaceutical research in Italy is increasingly specialized in biotechnologies, vaccines, blood products, orphan drugs and advanced therapies and plays an increasing role in clinical trials. These products require fast logistics, very attentive to the requirements of temperature stability and safe, we are talking about very high value therapies. The entry of Duimex’s skills into the PHSE family will strengthen our presence in the special services and clinical trials segment and will represent an important step in the development plan of the PHSE business towards supply chain solutions that are able to support the evolution of the Healthcare industry and patient access to innovative drugs.”
In order to give continuity to Duimex’s capabilities, the company will maintain its management autonomy. PHSE has fully confirmed the confidence in its business model which, like PHSE, is based on the management of transport with directly employed staff and owned vehicles.
